Brain Neoplasm Clinical Trial
Official title:
High Resolution Steady State Blood Volume Maps in Pediatric Brain Tumors Using MRI
This phase II trial studies ferumoxytol in the magnetic resonance imaging of pediatric patients with brain tumors. Magnetic resonance imaging using ferumoxytol may help in viewing a brain tumor and blood vessels in and around the tumor in a different way than the standard gadolinium-based contrast agent. Imaging with this experimental contrast agent may give doctors more information about tumor blood supply and the extent of the tumor itself.
PRIMARY OBJECTIVE: I. Testing the superiority of ferumoxytol-based steady state (SS)-cerebral blood volume (CBV) maps over gadolinium-based contrast agent (GBCA)-based dynamic susceptibility weighted (DSC)-CBV maps in visualizing pediatric brain tumor blood volume maps. SECONDARY OBJECTIVES: I. Correlation of relative cerebral blood volume (rCBV) with histology and genetic markers. II. Assessment of therapeutic response. III. Assessment of late ferumoxytol enhancement at various stages of disease. OUTLINE: Patients undergo magnetic resonance imaging (MRI) with GBCA per standard of care over 45-60 minutes and then receive ferumoxytol intravenously (IV) followed by MRI over 10 minutes on day 1. Patients may optionally undergo MRI over 30 minutes without any contrast agent on day 2. Each study visit consisting of 2 days may repeat no more frequently than 4 weeks for up to 5 study visits at different stages of the disease as determined by the investigator. After completion of study, patients are followed up at 2 and 6 weeks and then periodically for 5 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00001972 -
PET Scan of Brain Metabolism in Relation to Age and Disease
|
N/A | |
| Completed |
NCT02798406 -
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
|
Phase 2 | |
| Terminated |
NCT02855086 -
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
|
Phase 1/Phase 2 | |
| Terminated |
NCT00638963 -
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
|
Phase 2 | |
| Completed |
NCT00178295 -
Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury
|
N/A | |
| Recruiting |
NCT04810871 -
Surgical Resection of Latent Brain Tumors Prior to Recurrence
|
N/A | |
| Recruiting |
NCT02800486 -
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
|
Phase 2 | |
| Completed |
NCT01621295 -
Assessing the Patient Experience in Cancer Care
|
N/A | |
| Completed |
NCT02964416 -
Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery
|
Phase 4 | |
| Completed |
NCT00001574 -
A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
|
||
| Recruiting |
NCT02861898 -
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00040573 -
Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04553757 -
Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
|
||
| Recruiting |
NCT02754544 -
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
|
N/A | |
| Recruiting |
NCT03216148 -
18F-FET PET in Childhood Brain Tumours
|
Phase 2 | |
| Completed |
NCT00001171 -
Evaluation of Factors in Human Brain Tumors
|
N/A | |
| Withdrawn |
NCT01413438 -
Bevacizumab With or Without Surgery for Adult Glioblastomas
|
Phase 2 | |
| Not yet recruiting |
NCT05516485 -
Measuring Brain Tumor Consistency Using Magnetic Resonance Elastography
|
N/A | |
| Recruiting |
NCT02639325 -
Tumor Related Epilepsy
|
||
| Recruiting |
NCT02672995 -
Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial
|
Phase 1 |